Results 161 to 170 of about 279,790 (190)
Some of the next articles are maybe not open access.
CAR T-cells for cancer therapy
Biotechnology and Genetic Engineering Reviews, 2017Chimeric antigen receptor (CAR) T-cells are redirected T-cells that can recognize cancer antigens in a major histocompatibility complex (MHC)-independent fashion. A typical CAR is comprised of two main functional domains: an extracellular antigen recognition domain, called a single-chain variable fragment (scFv), and an intracellular signaling domain ...
Niaz, Muhammad, Qinwen, Mao, Haibin, Xia
openaire +2 more sources
CAR T-cell therapy for gliomas
Current Opinion in NeurologyPurpose of review To review the landscape of chimeric antigen receptor T-cell (CAR T) therapy for gliomas as seen in recently published trials and discuss on-going challenges with new cancer immunotherapy treatments. Recent findings Given how CAR T therapy has revolutionized the ...
Kun-Wei, Song, Brian J, Scott
openaire +2 more sources
CAR-T cell therapy and infection: a review
Expert Review of Anti-infective Therapy, 2020Introduction: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy) is a novel immunotherapy with promising results in the treatment of relapsed or refractory B cell malignancies. Patients undergoing CAR-T cell therapy are at increased risk of infection due to prior immunosuppression, lymphodepleting chemotherapy, treatment of unique toxicities
Olivia Bupha-Intr +5 more
openaire +2 more sources
Neurological Complications of CAR T Cell Therapy
Current Oncology Reports, 2020Chimeric antigen receptor (CAR) T cells are a breakthrough therapeutic treatment for patients with relapsed and refractory hematologic malignancies. With two FDA-approved formulations and likely more to come, CAR T cell therapy is moving beyond clinical trials and into academic and community oncology practices throughout the country.
Kara Landry, Alissa A. Thomas
openaire +2 more sources
Journal of Population Therapeutics and Clinical Pharmacology
There is rising interest in CAR-T therapy as a potential treatment of non-small cell lung cancer (NSCLC) that comprises about 85% of all lung cancer and has a high mortality rate. This is a new technology whereby T cells are engineered to attack certain tumor-specific antigens.
Dr. Renuka . +2 more
openaire +2 more sources
There is rising interest in CAR-T therapy as a potential treatment of non-small cell lung cancer (NSCLC) that comprises about 85% of all lung cancer and has a high mortality rate. This is a new technology whereby T cells are engineered to attack certain tumor-specific antigens.
Dr. Renuka . +2 more
openaire +2 more sources
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
The role of microbiome in CAR-T cell therapy
Chimeric Antigen Receptor (CAR) T-cell therapy represents a significant advancement in treating hematologic malignancies. However, its therapeutic efficacy against solid tumors remains hindered by several challenges, including suboptimal antitumor activity, high toxicity, and the emergence of resistance mechanisms.Reham, Abdel-Wahab +4 more
openaire +2 more sources